I think that is exactly the model that Mr. Ehrlich
Post# of 72435
If we got a modest 500 million up front for one of the drugs, the company could easily afford a $3-4 special dividend, and still fund further research on the other drugs. I'd love to see that
![](/images/icons/icon_biggrin.gif)
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)